PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 11 2023
Historique:
received: 20 05 2023
accepted: 30 10 2023
medline: 13 11 2023
pubmed: 11 11 2023
entrez: 10 11 2023
Statut: epublish

Résumé

The HIV-1 Tat protein hijacks the Super Elongation Complex (SEC) to stimulate viral transcription and replication. However, the mechanisms underlying Tat activation and inactivation, which mediate HIV-1 productive and latent infection, respectively, remain incompletely understood. Here, through a targeted complementary DNA (cDNA) expression screening, we identify PRMT2 as a key suppressor of Tat activation, thus contributing to proviral latency in multiple cell line latency models and in HIV-1-infected patient CD4

Identifiants

pubmed: 37949879
doi: 10.1038/s41467-023-43060-1
pii: 10.1038/s41467-023-43060-1
pmc: PMC10638354
doi:

Substances chimiques

Transcriptional Elongation Factors 0
tat Gene Products, Human Immunodeficiency Virus 0
AFF4 protein, human 0
PRMT2 protein, human EC 2.1.1.319
Protein-Arginine N-Methyltransferases EC 2.1.1.319
Intracellular Signaling Peptides and Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7274

Informations de copyright

© 2023. The Author(s).

Références

Life (Basel). 2021 Nov 19;11(11):
pubmed: 34833139
Genes Dev. 2014 Mar 15;28(6):622-36
pubmed: 24589551
Annu Rev Virol. 2017 Sep 29;4(1):261-285
pubmed: 28715973
J Virol. 1997 May;71(5):4098-102
pubmed: 9094689
Dev Cell. 2018 Apr 23;45(2):262-275.e8
pubmed: 29689199
J Clin Invest. 2001 Jan;107(2):143-51
pubmed: 11160127
Elife. 2013 Mar 05;2:e00327
pubmed: 23471103
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14047-52
pubmed: 12376617
Nat Commun. 2018 Oct 31;9(1):4552
pubmed: 30382083
PLoS Pathog. 2015 Jun 11;11(6):e1004955
pubmed: 26067822
J Leukoc Biol. 2012 Dec;92(6):1147-54
pubmed: 22802445
Cold Spring Harb Symp Quant Biol. 1998;63:371-80
pubmed: 10384302
J Mol Biol. 2022 Jan 15;434(1):167117
pubmed: 34174329
Mol Cell. 2010 Feb 12;37(3):429-37
pubmed: 20159561
PLoS Pathog. 2019 Aug 19;15(8):e1007991
pubmed: 31425551
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):E123-31
pubmed: 23251033
Elife. 2018 May 01;7:
pubmed: 29714165
Mol Cell. 2017 Jan 5;65(1):8-24
pubmed: 28061334
Mol Cell. 2010 May 14;38(3):428-38
pubmed: 20471948
Retrovirology. 2014 Jan 15;11:6
pubmed: 24428872
Nat Commun. 2017 May 24;8:15571
pubmed: 28537268
Mol Cell. 2006 Aug 4;23(3):297-305
pubmed: 16885020
Sci Adv. 2020 Apr 01;6(14):eaay4858
pubmed: 32270036
PLoS Pathog. 2019 Jan 15;15(1):e1007498
pubmed: 30645648
Nucleic Acids Res. 2013 Jan 7;41(1):277-87
pubmed: 23087374
Retrovirology. 2009 May 25;6:50
pubmed: 19467159
Nat Immunol. 2023 Feb;24(2):359-370
pubmed: 36536105
Cell Host Microbe. 2010 Mar 18;7(3):234-44
pubmed: 20227666
Elife. 2014 Apr 24;3:e02375
pubmed: 24843025
J Virol. 1990 Apr;64(4):1803-7
pubmed: 2108259
Nat Rev Mol Cell Biol. 2018 Jul;19(7):464-478
pubmed: 29740129
J Virol. 2005 Jan;79(1):124-31
pubmed: 15596808
Nature. 2020 Jan;577(7788):121-126
pubmed: 31853060
Sci Adv. 2023 Mar 10;9(10):eadf2468
pubmed: 36888719
FEBS J. 2017 Jan;284(1):77-96
pubmed: 27879050
Oncogene. 1998 Dec 17;17(24):3093-102
pubmed: 9872325
Cell Host Microbe. 2011 Nov 17;10(5):426-35
pubmed: 22100159
J Virol. 2007 Apr;81(8):4226-34
pubmed: 17267505
Sci Adv. 2020 May 13;6(20):eaaz8411
pubmed: 32426500
Nature. 2018 Jun;558(7709):318-323
pubmed: 29849146
J Biol Chem. 2016 Jul 29;291(31):16240-8
pubmed: 27235396
J Virol. 1998 Feb;72(2):1666-70
pubmed: 9445075
J Virol. 2008 Dec;82(24):12291-303
pubmed: 18829756
Proc Natl Acad Sci U S A. 1988 Dec;85(24):9406-10
pubmed: 3200827
Curr Opin HIV AIDS. 2016 Jul;11(4):394-401
pubmed: 26974532

Auteurs

Jiaxing Jin (J)

National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease of Ministry of Education, Department of Cell Biology, School of Basic Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, 300070, Tianjin, China.

Hui Bai (H)

National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease of Ministry of Education, Department of Cell Biology, School of Basic Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, 300070, Tianjin, China.

Han Yan (H)

National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease of Ministry of Education, Department of Cell Biology, School of Basic Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, 300070, Tianjin, China.

Ting Deng (T)

Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.

Tianyu Li (T)

Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.

Ruijing Xiao (R)

Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.

Lina Fan (L)

Department of Infectious Diseases, Tianjin Second People's Hospital, Nankai University, 300192, Tianjin, China.

Xue Bai (X)

The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.

Hanhan Ning (H)

National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease of Ministry of Education, Department of Cell Biology, School of Basic Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, 300070, Tianjin, China.

Zhe Liu (Z)

The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.

Kai Zhang (K)

The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.

Xudong Wu (X)

The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.

Kaiwei Liang (K)

Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.

Ping Ma (P)

Department of Infectious Diseases, Tianjin Second People's Hospital, Nankai University, 300192, Tianjin, China. docmaping@outlook.com.

Xin Gao (X)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China. gaoxin1@ihcams.ac.cn.
Tianjin Institutes of Health Science, 301600, Tianjin, China. gaoxin1@ihcams.ac.cn.

Deqing Hu (D)

National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease of Ministry of Education, Department of Cell Biology, School of Basic Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, 300070, Tianjin, China. hudq@tmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH